Dimerix Limited (SBMJF)

Market Cap	210.09M
Revenue (ttm)	3.66M
Net Income (ttm)	-8.69M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214
Average Volume	4,416
Open	0.3500
Previous Close	0.2500
Day's Range	0.3500 - 0.3500
52-Week Range	0.2500 - 0.3500
Beta	0.31
RSI	n/a
Earnings Date	Aug 28, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: SBMJF

Financial Performance

In 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.

Financial numbers in AUD